Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development

Open access
Ivens, Inge A., Achanzar, William, Baumann, Andreas, Brändli-Baiocco, Annamaria, Cavagnaro, Joy, Dempster, Maggie, Depelchin, B. Olympe, Irizarry Rovira, Armando R., Dill-Morton, Laura, Lane, Joan H., Reipert, Birgit M., Salcedo, Theodora, Schweighardt, Becky, Tsuruda, Laurie S., Turecek, Peter L., Sims, Jennifer·2015·Toxicologic Pathology

Abstract

PEGylation (the covalent binding of one or more polyethylene glycol molecules to another molecule) is a technology frequently used to improve the half-life and other pharmaceutical or pharmacological properties of proteins, peptides, and aptamers. To date, 11 PEGylated biopharmaceuticals have been approved and there is indication that many more are in nonclinical or clinical development. Adverse effects seen with those in toxicology studies are mostly related to the active part of the drug molecule and not to polyethylene glycol (PEG). In 5 of the 11 approved and 10 of the 17 PEGylated biopharmaceuticals in a 2013 industry survey presented here, cellular vacuolation is histologically observed in toxicology studies in certain organs and tissues. No other effects attributed to PEG alone have been reported. Importantly, vacuolation, which occurs mainly in phagocytes, has not been linked with changes in organ function in these toxicology studies. This article was authored through collaborative efforts of industry toxicologists/nonclinical scientists to address the nonclinical safety of large PEG molecules (>10 kilo Dalton) in PEGylated biopharmaceuticals. The impact of the PEG molecule on overall nonclinical safety assessments of PEGylated biopharmaceuticals is discussed, and toxicological information from a 2013 industry survey on PEGylated biopharmaceuticals under development is summarized. Results will contribute to the database of toxicological information publicly available for PEG and PEGylated biopharmaceuticals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0192623315591171

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 158

Metadata

Authors
Ivens, I. A., Achanzar, W., Baumann, A., Brändli-Baiocco, A., Cavagnaro, J., Dempster, M., Depelchin, B. O., Irizarry Rovira, A. R., Dill-Morton, L., Lane, J. H., Reipert, B. M., Salcedo, T., Schweighardt, B., Tsuruda, L. S., Turecek, P. L., & Sims, J.
Venue
Toxicologic Pathology
Published
2015-08-03
Volume
43
Issue
7
Pages
959-983
ISSN
  • 0192-6233 (ISSN-L)
  • 1533-1601
OpenAlex
W2179446546
Cited by
158
References
5
FWCI
5.63
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development. https://app.cochat.ai/papers/10.1177/0192623315591171
The paper
Ivens, I. A., Achanzar, W., Baumann, A., Brändli-Baiocco, A., Cavagnaro, J., Dempster, M., Depelchin, B. O., Irizarry Rovira, A. R., Dill-Morton, L., Lane, J. H., Reipert, B. M., Salcedo, T., Schweighardt, B., Tsuruda, L. S., Turecek, P. L., & Sims, J. (2015). PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development. Toxicologic Pathology. https://doi.org/10.1177/0192623315591171

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.